Your browser doesn't support javascript.
loading
Characteristics and outcomes of 118,155 COVID-19 individuals with a history of cancer in the United States and Spain
Elena Roel Mrs; Andrea Pistillo Mr; Martina Recalde Mrs; Anthony G Sena Mr; Sergio Fernandez-Bertolin Mr; Maria Aragon Mrs; Diana Puente Dr; Waheed-Ul-Rahman Ahmed Mr; Heba Alghoul Mr; Osaid Alser Mr; Thamir M Alshammari Dr; Carlos Areia Mr; Clair Blacketer Mrs; William Carter Mr; Paula Casajust Mrs; Aedin C Culhane Dr; Dalia Dawoud Dr; Frank DeFalco Mr; Scott L Duvall Dr; Thomas Falconer Mr; Asieh Golozar Dr; Mengchun Gong Mr; Laura Hester Dr; George Hripcsak Mr; Eng Hooi Tan Dr; Hokyun Jeon Mr; Jitendra Jonnagaddala Dr; Lana YH Lai Dr; Kristine E Lynch Dr; Michael E Matheny Mr; Daniel R Morales Dr; Karthik Natarajan Dr; Fredrik Nyberg Dr; Anna Ostropolets Mrs; Jose D Posada Dr; Albert Prats-Uribe Mr; Christian G Reich Dr; Donna Rivera Mrs; Lisa M Schilling Mrs; Isabelle Soerjomataram Dr; Karishma Shah Mrs; Nigam Shah Dr; Yang Shen Mr; Matthew Spotnitz Mr; Vignesh Subbian Dr; Marc A Suchard Dr; Annalisa Trama Dr; Lin Zhang Dr; Ying Zhang Dr; Patrick Ryan Dr; Daniel Prieto-Alhambra Dr; Kristin Kostka Mrs; Talita Duarte-Salles Dr.
Afiliación
  • Elena Roel Mrs; Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
  • Andrea Pistillo Mr; Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
  • Martina Recalde Mrs; Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
  • Anthony G Sena Mr; Janssen Research and Development, Titusville, NJ USA
  • Sergio Fernandez-Bertolin Mr; Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
  • Maria Aragon Mrs; Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
  • Diana Puente Dr; Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
  • Waheed-Ul-Rahman Ahmed Mr; Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Windmill Road, Oxford, OX3 7LD, U
  • Heba Alghoul Mr; Faculty of Medicine, Islamic University of Gaza, Palestine
  • Osaid Alser Mr; Massachusetts General Hospital, Harvard Medical School, USA
  • Thamir M Alshammari Dr; Medication Safety Research Chair, King Saud University
  • Carlos Areia Mr; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK
  • Clair Blacketer Mrs; Janssen Research and Development, Titusville, NJ USA
  • William Carter Mr; Data Science to Patient Value Program, Department of Medicine, University of Colorado Anschutz Medical Campus
  • Paula Casajust Mrs; Real-World Evidence, Trial Form Support, Barcelona, Spain
  • Aedin C Culhane Dr; Department of Data Science, Dana-Farber Cancer Institute, Boston MA, USA
  • Dalia Dawoud Dr; Faculty of Pharmacy, Cairo University, Cairo, Egypt
  • Frank DeFalco Mr; Janssen Research & Development, Titusville, NJ, USA
  • Scott L Duvall Dr; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA
  • Thomas Falconer Mr; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY 10032, USA New York-Presbyterian Hospital, 622 W 168 St, PH20 New
  • Asieh Golozar Dr; Department of Epidemiology, Johns Hopkins School of Public, Baltimore MD, USA
  • Mengchun Gong Mr; HDC Technologies Co. Ltd. Beijing, China
  • Laura Hester Dr; Associate Director, Epidemiology, Janssen Research and Development, LLC.
  • George Hripcsak Mr; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY 10032, USA
  • Eng Hooi Tan Dr; Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, OX3 7LD, UK
  • Hokyun Jeon Mr; Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Gyeonggi do, Republic of Korea
  • Jitendra Jonnagaddala Dr; School of Public Health and Community Medicine, UNSW Sydney
  • Lana YH Lai Dr; School of Medical Sciences, University of Manchester, UK
  • Kristine E Lynch Dr; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA
  • Michael E Matheny Mr; Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, TN, USA
  • Daniel R Morales Dr; Division of Population Health and Genomics, University of Dundee, UK
  • Karthik Natarajan Dr; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY 10032, USA
  • Fredrik Nyberg Dr; School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
  • Anna Ostropolets Mrs; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY 10032, USA
  • Jose D Posada Dr; Department of Medicine, School of Medicine, Stanford University, Redwood City, CA USA
  • Albert Prats-Uribe Mr; Centre for Statistics in Medicine, NDORMS, University of Oxford
  • Christian G Reich Dr; Real World Solutions, IQVIA, Cambridge, MA USA
  • Donna Rivera Mrs; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD
  • Lisa M Schilling Mrs; Department of Medicine, Data Science to Patient Value Program, University of Colorado Anschutz Medical Campus
  • Isabelle Soerjomataram Dr; Section of Cancer Surveillance, International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69008 Lyon, France
  • Karishma Shah Mrs; Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Windmill Road, Oxford, OX3 7LD, U
  • Nigam Shah Dr; Department of Medicine, School of Medicine, Stanford University, Redwood City, CA USA
  • Yang Shen Mr; HDC Technologies Co. Ltd. Beijing, China
  • Matthew Spotnitz Mr; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY 10032, USA
  • Vignesh Subbian Dr; College of Engineering, The University of Arizona, Tucson, Arizona, USA
  • Marc A Suchard Dr; Fielding School of Public Health, University of California, Los Angeles
  • Annalisa Trama Dr; Fondazione IRCSS Istituto Nazionale dei Tumori, Milan - Italy
  • Lin Zhang Dr; School of Population Medicine and Public Health, Peking Union Medical College, Chinese Academy of Medical Sciences.
  • Ying Zhang Dr; Janssen Research & Development, Titusville, NJ, USA
  • Patrick Ryan Dr; Janssen Research & Development, Titusville, NJ, USA
  • Daniel Prieto-Alhambra Dr; Centre for Statistics in Medicine, NDORMS, University of Oxford
  • Kristin Kostka Mrs; Real World Solutions, IQVIA, Cambridge, MA USA
  • Talita Duarte-Salles Dr; Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21249672
ABSTRACT
PurposeWe aimed to describe the demographics, cancer subtypes, comorbidities and outcomes of patients with a history of cancer with COVID-19 from March to June 2020. Secondly, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza. MethodsWe conducted a cohort study using eight routinely-collected healthcare databases from Spain and the US, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included i) diagnosed with COVID-19, ii) hospitalized with COVID-19, and iii) hospitalized with influenza in 2017-2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes. ResultsWe included 118,155 patients with a cancer history in the COVID-19 diagnosed and 41,939 in the COVID-19 hospitalized cohorts. The most frequent cancer subtypes were prostate and breast cancer (range 5-19% and 1-14% in the diagnosed cohort, respectively). Hematological malignancies were also frequent, with non-Hodgkins lymphoma being among the 5 most common cancer subtypes in the diagnosed cohort. Overall, patients were more frequently aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 8% to 14% and from 18% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n=242,960) had a similar distribution of cancer subtypes, sex, age and comorbidities but lower occurrence of adverse events. ConclusionPatients with a history of cancer and COVID-19 have advanced age, multiple comorbidities, and a high occurence of COVID-19-related events. Additionaly, hematological malignancies were frequent in these patients.This observational study provides epidemiologic characteristics that can inform clinical care and future etiological studies.
Licencia
cc_by
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Cohort_studies / Etiology_studies / Observational_studies / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Cohort_studies / Etiology_studies / Observational_studies / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint